Wolfgang A Schmidt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11365872/publications.pdf

Version: 2024-02-01

62	6,571	126858	133188
papers	citations	33	59
		h-index	g-index

65	65	65	3862
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Musculoskeletal ultrasound including definitions for ultrasonographic pathology. Journal of Rheumatology, 2005, 32, 2485-7.	1.0	848
2	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, 636-643.	0.5	753
3	Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis. New England Journal of Medicine, 1997, 337, 1336-1342.	13.9	660
4	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 804-814.	0.5	504
5	Meta-Analysis: Test Performance of Ultrasonography for Giant-Cell Arteritis. Annals of Internal Medicine, 2005, 142, 359.	2.0	323
6	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 2016, 20, 1-238.	1.3	313
7	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
8	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. Annals of the Rheumatic Diseases, 2017, 76, 1974-1979.	0.5	191
9	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open, 2018, 4, e000598.	1.8	155
10	Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open, 2017, 3, e000427.	1.8	149
11	Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology, 2018, 57, ii22-ii31.	0.9	139
12	OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On. Journal of Rheumatology, 2019, 46, 1388-1393.	1.0	133
13	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
14	International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. Rheumatology, 2015, 54, 1797-1805.	0.9	122
15	Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology, 2017, 56, 1479-1483.	0.9	122
16	Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Current Opinion in Rheumatology, 2005, 17, 9-15.	2.0	115
17	The OMERACT Ultrasound Task Force â€" Status and Perspectives. Journal of Rheumatology, 2011, 38, 2063-2067.	1.0	111
18	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology, 2018, 57, 227-235.	0.9	101

#	Article	IF	Citations
19	The Diagnosis and Treatment of Giant Cell Arteritis. Deutsches Ärzteblatt International, 2013, 110, 376-85; quiz 386.	0.6	100
20	Role of ultrasound in the understanding and management of vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 39-47.	1.2	82
21	What is the best approach to diagnosing large-vessel vasculitis?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 223-242.	1.4	78
22	The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12â€…months of therapy. Annals of the Rheumatic Diseases, 2013, 72, 1163-1169.	0.5	77
23	Imaging in vasculitis. Best Practice and Research in Clinical Rheumatology, 2013, 27, 107-118.	1.4	74
24	Current state of musculoskeletal ultrasound training and implementation in Europe: results of a survey of experts and scientific societies. Rheumatology, 2010, 49, 2438-2443.	0.9	65
25	Imaging of vasculitis: State of the art. Best Practice and Research in Clinical Rheumatology, 2016, 30, 688-706.	1.4	64
26	Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology, 2018, 57, 318-321.	0.9	60
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
28	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology, 2018, 57, 112-119.	0.9	53
29	Technology Insight: the role of color and power Doppler ultrasonography in rheumatology. Nature Clinical Practice Rheumatology, 2007, 3, 35-42.	3.2	52
30	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. Journal of Rheumatology, 2018, 45, 1289-1295.	1.0	49
31	Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis?. Rheumatology, 2009, 48, 383-385.	0.9	46
32	Ultrasonography in inflammatory rheumatic disease: an overview. Nature Reviews Rheumatology, 2011, 7, 479-488.	3.5	38
33	Doppler sonography in rheumatology. Best Practice and Research in Clinical Rheumatology, 2004, 18, 827-846.	1.4	35
34	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.5	34
35	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Annals of the Rheumatic Diseases, 2021, 80, 1475-1482.	0.5	34
36	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.5	31

#	Article	IF	Citations
37	Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials, 2021, 22, 543.	0.7	31
38	Head-to-head comparison of quantitative and semi-quantitative ultrasound scoring systems for rheumatoid arthritis: reliability, agreement and construct validity. Rheumatology, 2012, 51, 2034-2038.	0.9	30
39	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology, 2020, 59, 3717-3726.	0.9	26
40	Investigations in systemic vasculitis â€“ The role of imaging. Best Practice and Research in Clinical Rheumatology, 2018, 32, 63-82.	1.4	25
41	Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. Rheumatology, 2021, 60, 5052-5059.	0.9	25
42	Takayasu and Temporal Arteritis. , 2006, 21, 96-104.		23
43	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. International Journal of Rheumatology, 2009, 2009, 1-5.	0.9	23
44	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	0.9	21
45	Current diagnosis and treatment of temporal arteritis. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 145-151.	0.4	20
46	Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides. Arthritis and Rheumatology, 2019, 71, 1780-1787.	2.9	19
47	The ultrasound halo sign of temporal arteries: is it always giant cell arteritis?. Rheumatology, 2019, 58, 1898-1899.	0.9	18
48	What the practising rheumatologist needs to know about the technical fundamentals of ultrasonography. Best Practice and Research in Clinical Rheumatology, 2008, 22, 981-999.	1.4	17
49	The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. Rheumatology, 2012, 51, vii26-vii30.	0.9	17
50	Imaging in large-vessel vasculitis. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101589.	1.4	15
51	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology, 2021, 60, 4361-4366.	0.9	15
52	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. Lancet Rheumatology, The, 2021, 3, e886-e895.	2.2	15
53	Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199850.	1.2	14
54	OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. Seminars in Arthritis and Rheumatism, 2021, 51, 951-956.	1.6	13

#	Article	IF	Citations
55	Role of imaging in diagnosis of and differentiation between vasculitides. Future Rheumatology, 2006, 1, 627-634.	0.2	10
56	Temporal arteritis with ultrasound halo sign in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2069-2071.	0.9	8
57	Ultrasound in Rheumatology. International Journal of Rheumatic Diseases, 2014, 17, 711-715.	0.9	4
58	Whole-body MRI in RA: do we still need the rheumatologist?. Nature Reviews Rheumatology, 2014, 10, 130-132.	3.5	2
59	Response to: â€˜The role of temporal artery biopsy in patients with giant cell arteritis is debatedâ€™ by Moiseev et al. Annals of the Rheumatic Diseases, 2019, 78, e32-e32.	0.5	1
60	Introduction: Musculoskeletal Ultrasound Indications and Fundamentals. , 2021, , 1-20.		1
61	FRI0274â€…ULTRASOUND CUT-OFF VALUE FOR INTIMA-MEDIA THICKNESS OF THE AXILLARY ARTERIES IN PATIENTS WITH CHRONIC LARGE-VESSEL GIANT CELL ARTERITIS. , 2019, , .		0
62	Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly. , 2011, , 225-229.		0